Free Trial
NASDAQ:ALXN

Alexion Pharmaceuticals (ALXN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$182.50
$182.50
50-Day Range
$179.45
$186.61
52-Week Range
$99.91
$187.45
Volume
10 shs
Average Volume
3.31 million shs
Market Capitalization
$40.34 billion
P/E Ratio
59.64
Dividend Yield
N/A
Price Target
N/A
ALXN stock logo

About Alexion Pharmaceuticals Stock (NASDAQ:ALXN)

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

ALXN Stock News Headlines

Home To The World’s Largest High-Grade Uranium Deposits
Nuclear is one of the safest forms of energy around. In its entire history, nuclear is responsible for fewer deaths than oil and gas pollution cause every year. And investors are eyeing uranium exploration companies as one of the surest plays on the current nuclear renaissance.
BioMarin Pharma gains on report Elliott has a stake
Home To The World’s Largest High-Grade Uranium Deposits
Nuclear is one of the safest forms of energy around. In its entire history, nuclear is responsible for fewer deaths than oil and gas pollution cause every year. And investors are eyeing uranium exploration companies as one of the surest plays on the current nuclear renaissance.
Alexion Pharmaceuticals Inc (A1LX34)
Alexion Reaches New 52-Week High (ALXN)
See More Headlines
Receive ALXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alexion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/29/2021
Today
7/17/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ALXN
CUSIP
01535110
Fax
N/A
Employees
3,837
Year Founded
1992

Profitability

Net Income
$603.40 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$6.07 billion
Cash Flow
$22.81 per share
Book Value
$53.24 per share

Miscellaneous

Free Float
N/A
Market Cap
$40.34 billion
Optionable
Optionable
Beta
1.25

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Should I Buy Alexion Pharmaceuticals Stock? ALXN Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Alexion Pharmaceuticals, Inc.:

  • No recent pro reasons available for Alexion Pharmaceuticals, Inc.

Cons

Investors should be bearish about investing in Alexion Pharmaceuticals, Inc. for these reasons:

  • No recent con reasons available for Alexion Pharmaceuticals, Inc.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, July 7, 2024. Please send any questions or comments about these Alexion Pharmaceuticals pros and cons to contact@marketbeat.com.

ALXN Stock Analysis - Frequently Asked Questions

How were Alexion Pharmaceuticals' earnings last quarter?

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) released its earnings results on Thursday, April, 29th. The biopharmaceutical company reported $3.52 EPS for the quarter, topping the consensus estimate of $3.16 by $0.36. The firm's revenue was up 13.3% on a year-over-year basis.

What is Ludwig Hantson's approval rating as Alexion Pharmaceuticals' CEO?

43 employees have rated Alexion Pharmaceuticals Chief Executive Officer Ludwig Hantson on Glassdoor.com. Ludwig Hantson has an approval rating of 75% among the company's employees.

Does Alexion Pharmaceuticals have any subsidiaries?

The following companies are subsidiaries of Alexion Pharmaceuticals: Portola Pharmaceuticals Inc., Achillion Pharmaceuticals, Syntimmune, Wilson Therapeutics, Synageva BioPharma Corp., Enobia Pharma Corp., Taligen Therapeutics Inc., and more.

What other stocks do shareholders of Alexion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alexion Pharmaceuticals investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU), AbbVie (ABBV) and Tesla (TSLA).

This page (NASDAQ:ALXN) was last updated on 7/18/2024 by MarketBeat.com Staff

From Our Partners